790304-99-3

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-methyl 2-(tert-butoxycarbonylamino)-3-(pent-4-enyloxy)propanoate is used as a building block in the pharmaceutical industry for the preparation of biologically active compounds. Its unique structure allows for versatile chemical modifications, such as deprotection of the amino group, ester hydrolysis, and cross-coupling reactions, to create a variety of new molecules with potential therapeutic applications.
Used in Organic Synthesis Research:
In the field of organic chemistry, (S)-methyl 2-(tert-butoxycarbonylamino)-3-(pent-4-enyloxy)propanoate serves as an important intermediate for the development of novel synthetic pathways and methodologies. Its specific stereochemistry and functional groups make it an intriguing subject for research aimed at understanding and exploiting the reactivity and selectivity of complex organic molecules.
Used in Medicinal Chemistry Research:
(S)-methyl 2-(tert-butoxycarbonylamino)-3-(pent-4-enyloxy)propanoate is utilized in medicinal chemistry as a key intermediate for the design and synthesis of new drug candidates. Its unique structural elements can be leveraged to explore the structure-activity relationships of potential therapeutic agents, contributing to the advancement of drug discovery efforts.

Upstream product

• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 1119-51-3 bromopentene 
• 74-88-4 methyl iodide 
• 790305-00-9 (S)-2-(((tert-butoxy)carbonyl)amino)-3-(pent-4-enyloxy)propanoic acid 

Downstream Products

• 1338650-05-7 1-{[4-(4-bromobenzenesulfonyloxy)-1-(2-cyclopentyloxycarbonylamino-3-pent-4-enyloxypropionyl)pyrrolidine-2-carbonyl]amino}-2-vinylcyclopropanecarboxylic acid ethyl ester 
• 790305-00-9 (S)-2-(((tert-butoxy)carbonyl)amino)-3-(pent-4-enyloxy)propanoic acid 

Relevant academic research and scientific papers

A concise synthesis of the HCV protease inhibitor BILN 2061 and its P3 modified analogs

A concise synthesis of BILN 2061 was achieved through more efficient installation of P2 4-quinoline moiety via SN2 displacement of the β-OBs group located on the 4-hydroxyl proline intermediate, which was prepared from 4-α-hydroxyl proline analog via Mitsunobu reaction with inversion of stereochemistry. In addition, a short and practical synthesis for P3 unit is also described herein. Final assembly of four fragments for BILN 2061 was achieved with an overall yield of 58% in 4 steps from P1 to 15a. Furthermore several analogs of BILN 2061 (WX-1-WX-5) containing modifications on P3 unit were synthesized successfully using the same synthetic route as described for the parent inhibitor BILN 2061. Copyright

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R′3, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula (I): are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Macrocyclic peptides are disclosed having the general formula: wherein R′, R3, R3′, R4, R6, X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.